<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-H4J1KE6J</identifier><date>2023</date><creator>Cvetanoska, Maja</creator><creator>Kozina Bubnič, Lara</creator><relation>documents/doc/H/URN_NBN_SI_doc-H4J1KE6J_001.pdf</relation><relation>documents/doc/H/URN_NBN_SI_doc-H4J1KE6J_001.txt</relation><format format_type="issue">2</format><format format_type="type">article</format><format format_type="extent">str. 26-29</format><identifier identifier_type="COBISSID_HOST">166023939</identifier><identifier identifier_type="ISSN">2820-5006</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-H4J1KE6J</identifier><language>slv</language><publisher publisher_location="Ljubljana">Fakulteta za farmacijo, ŠSSFD</publisher><source>Placebo</source><rights>InC</rights><subject language_type_id="slv">hematološke rakave bolezni</subject><subject language_type_id="slv">himerni antigenski receptor</subject><subject language_type_id="slv">Imunoterapija</subject><subject language_type_id="slv">limfociti T</subject><subject language_type_id="slv">rakave celice</subject><subject language_type_id="slv">terapija CAR-T</subject><subject language_type_id="slv">tumorsko mikrookolje</subject><title>Celična terapija CAR-T</title></Record>